Pricing the Next Wave of COPD Therapies: Lessons from Current Reimbursement Patterns
Read More
June 2026
The US Gets Entresto® for a Steal
The US market-based price for Entresto® is a steal—priced less than the benefit it is expected to provide.
Entresto® (sacubitril/valsartan, developed by Novartis Pharmaceuticals Corporation) was approved in 2015 for heart failure. The launch price for Entresto was around $4,500 per year. A conventional cost-effectiveness analysis from the health system perspective suggests this price is cost-effective even when assuming this price stays constant forever. Entresto could be priced between $11,000 and $17,000 per year before meeting commonly used thresholds for cost-effectiveness.
This suggests that the US market-based price for Entresto is less than the benefit it is expected to provide. Despite this, downward pressures to the price of Entresto are coming—whether due to the Medicare Drug Price Negotiation Program price going into effect in 2026 or due to the expected loss of exclusivity and subsequent entrants of generic equivalents in as early as a few months.
Because of these upcoming changes, we selected sacubitril/valsartan to be the topic of this CPE Exclusive. In this CPE Exclusive, we updated our conventional cost-effectiveness analysis to incorporate price dynamics based on the price changes to date and the expected price declines in the future. Incorporating these price changes into the economic model suggested that sacubitril/valsartan was even more cost-effective than initially modeled.
Considering the allocation of sacubitril/valsartan’s benefit between the manufacturer and society, society is expected to receive the majority share of its benefit.
Read our full report for a description of our modeling assumptions and detailed model findings.
The US Gets Entresto® for a Steal
Click here to read the full report.
Download Our Exclusive Content
Thank you for your interest in Leerink Partners’ proprietary content. To access the PDF, please enter your contact information below.
The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners
Leerink Center for Pharmacoeconomics
– Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
